Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 233,297,166 papers from all fields of science
Search
Sign In
Create Free Account
NovoTTF-100A Device
Known as:
NovoTumor Treatment Fields
, NovoTTFields
, Optune Device
Expand
A portable, battery-operated device that is used to apply low intensity, alternating electric fields, also called tumor treatment fields (TTFs…
Expand
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
NovoTTF-100A System as a treatment for Glioblastoma
A. Morrison
2018
Corpus ID: 81441076
Background: Glioblastoma is an aggressive malignant brain tumor with exceptionally poor prognosis. Currently, patients with this…
Expand
2014
2014
ED-38AN UPDATED ANALYSIS OF PATIENT REGISTRY DATA ON NOVOTTF-100A ALTERNATING ELECTRIC FIELDS THERAPY FOR RECURRENT GLIOBLASTOMA
E. Wong
,
H. Engelhard
,
+8 authors
Jay-Jiguang Zhu
2014
Corpus ID: 55009018
The NovoTTF-100A System is an anticancer treatment that emits alternating electric fields, at an intensity of 1 V/cm and a…
Expand
2014
2014
P17.60NOVO-TTF 100A SYSTEM USED SUCCESSFULLY IN A PATIENT WITH A VENTRICULO-PERITONEAL SHUNT.
M. Mrugala
,
C. Graham
,
J. Rockhill
,
D. Silbergeld
2014
Corpus ID: 71939107
BACKGROUND: NovoTTF-100A system is a new modality of treatment approved for therapy of recurrent glioblastoma. Most patients with…
Expand
2014
2014
Title Clinical Practice Experience With NovoTTF-100 A ( TM ) System for Glioblastoma : The Patient Registry Dataset ( PRiDe ) Permalink
2014
Corpus ID: 54814383
s). 2010;12(suppl 4) (NO-54). 23. Wong ET, Lok E, Swanson KD, Gautam S, Engelhard HH, Lieberman F, et al. Response assessment of…
Expand
Review
2014
Review
2014
NT-25EARLY JAPANESE EXPERIENCE WITH NovoTTF-100A SYSTEM FOR RECURRENT GBM
Y. Muragaki
,
M. Nitta
,
+4 authors
I. Suzuki
2014
Corpus ID: 75911791
BACKGROUND: NovoTTF-100A System is an FDA-approved treatment for recurrent glioblastoma (GBM) and is defined as a device of high…
Expand
Review
2014
Review
2014
NT-26PATHOLOGY OF CASES OF IMAGING PROGRESSION IN PATIENTS DIAGNOSED WITH GLIOBLASTOMA WHO HAVE BEEN TREATED WITH THE NOVOCURE - TTF DEVICE IN THE EF-14 TRIAL
P. New
,
S. Powell
2014
Corpus ID: 71416721
INTRODUCTION: The diagnosis of glioblastoma carries a dismal prognosis with an average of 14 months survival with standard…
Expand
2013
2013
Safety analysis of bevacizumab plus NovoTTF-100A in patients with recurrent malignant gliomas.
G. Elzinga
,
Amy Chung
,
E. Wong
2013
Corpus ID: 198379326
2082 Background: Both bevacizumab and the NovoTTF-100A device are treatments approved by the FDA for recurrent glioblastoma. We…
Expand
2013
2013
NovoTTF-100A versus Chemotherapie
C. Nieder
Info Onkologie
2013
Corpus ID: 77702771
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE